Loading stock data…
FMS
$22.65+0.16 (+0.71%)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fresenius Medical Care AG in the Healthcare sector is trading at $22.65. The stock is currently near its 52-week low of $20.95, remaining 6.3% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why FMS maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$22.65
Potential Upside
64.5%
Whystock Fair Value$37.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Hold
Mean target$27.42+21.0%
Range$18.33 – $38.44
Fundamentals
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a ne...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.43B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.54
Beta
Defensive asset. Lower volatility than the S&P 500.
0.85
Div Yield
Strong income play. Yield provides a meaningful total return floor.
357.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.93%
Volume
Today's trading volume
675,641
Recent News
A Look At Fresenius Medical Care (XTRA:FME) Valuation After The Symvess Distribution Agreement Revision
Fresenius Medical Care (XTRA:FME) is back in focus after Humacyte adjusted the ex U.S. distribution rights for Symvess, an acellular tissue engineered vessel, reshaping how the partners approach vascular access and regenerative medicine abroad. See our latest analysis for Fresenius Medical Care. The amended Symvess agreement lands at a time when Fresenius Medical Care’s €38.61 share price has seen a modest 1.34% 90 day share price return but a 12.44% decline in 1 year total shareholder...
Fresenius Medical Care’s Symvess Deal Shift And What It Means For Valuation
Fresenius Medical Care and Humacyte have amended their international rights agreement for Symvess, an acellular tissue engineered vessel. The revised deal realigns ex U.S. distribution rights, affecting how Symvess may be brought to markets outside the United States. The change reflects an adjustment in how the two companies plan to collaborate in vascular access and regenerative medicine globally. Fresenius Medical Care (XTRA:FME), trading at around €38.61, is adjusting its product...
BrightSpring Before Q1 Earnings: Buy, Sell or Hold the Stock Now?
BTSG heads into Q1 earnings with strong pharmacy and home-care momentum, but margin pressures, integration costs and slower growth may temper expectations.
Baxter Q1 Preview: Will Operational Headwinds Weigh on Results Again?
BAX heads into Q1 earnings with revenues and profit set to fall sharply as operational pressures, weak demand and product disruptions weigh on results.
Quest Diagnostics Q1 Earnings Call Highlights
Quest Diagnostics (NYSE:DGX) reported first-quarter 2026 results that management said reflected broad-based organic growth, improving productivity from automation and artificial intelligence, and contributions from major collaborations including Fresenius Medical Care and Corewell Health. The compan